BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

09/730,814

CAS ONLINE PRINTOUT

> d his

(FILE 'HOME' ENTERED AT 09:32:53 ON 27 SEP 2001)

FILE 'CAPLUS' ENTERED AT 09:33:08 ON 27 SEP 2001
E KYLE D/AU
E KYLE DON/AU
L1 55 S E4-E6
L2 0 S GOEHRING RIC/AU
E GOEHRING RIC/AU
L3 3 S E4-E5
L4 0 S L3 AND L2
L5 1 S L1 AND L3
SELECT RN L5 1

FILE 'REGISTRY' ENTERED AT 09:35:47 ON 27 SEP 2001
L6 24 S E1-E24

FILE 'REGISTRY' ENTERED AT 09:49:21 ON 27 SEP 2001
L7 STRUCTURE UPLOADED
L8 QUE L7
L9 19 S L8
L10 STRUCTURE UPLOADED
L11 3 S L10
L12 432 S L10 FUL
L13 STRUCTURE UPLOADED
L14 8 SEARCH L13 CSS SUB=L12 FULL

FILE 'CAPLUS' ENTERED AT 09:57:11 ON 27 SEP 2001
L15 5 S L14

=> d l13
L13 HAS NO ANSWERS
L13 STR



G1 Me,Et,n-Pr,i-Pr,n-Bu,i-Bu,s-Bu,t-Bu,H
G2 H,O

Structure attributes must be viewed using STN Express query preparation.

CAS ONLINE PRINTOUT

=> d bib abs hitstr 1-5

L15 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2001 ACS
AN 2001:416763 CAPLUS
DN 135:33362
TI Preparation of tertiary amino compounds having opioid receptor affinity
IN Kyle, Donald; Goehring, R. Richard; Victory, Sam
PA Euro-Celtique, S.A., Luxembourg
SO PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001039767	A1	20010607	WO 2000-US33047	20001206

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1999-169396 P 19991206
OS MARPAT 135:33362
GI



I

AB The title compds. [I; R1 = a bond, alkenylene, etc.; R2, R3 = H, alkyl, alkenyl, etc.; R4 = a bond, alkenylene, etc.; R5 = H, 5-6 membered (hetero)aryl, cycloalkyl; R6 = alkyl, cycloalkyl, halo; n = 0-3], useful for the treatment of chronic and acute pain, were prepd. Thus, reacting benzaldehyde with 3-(dibutylamino)propylamine in the presence of NaBH4, 3.ANG. mol. sieves in MeOH followed by amidataion of the resulting I [R1 = (CH2)3; R2, R3 = Bu; R4 = a bond; R5, R6 = H] with phenylacetic acid in the presence of EDCl and DMAP in THF afforded I [R1 = (CH2)3; R2, R3 = Bu; R4 = COCH2; R5 = Ph; R6 = H] which showed Ki of 40 nM against opioid receptor .mu. binding.

IT **343593-68-0P 343593-69-1P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of tertiary amino compds. having opioid receptor affinity)

RN 343593-68-0 CAPLUS
CN Benzeneacetamide, N-[3-(dibutylamino)propyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

CAS ONLINE PRINTOUT



RN 343593-69-1 CAPLUS
CN Benzeneacetamide, N-[2-(dimethylamino)ethyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RE.CNT 1
RE
(1) Lowrie; US 3843657 A 1974 CAPLUS

L15 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2001 ACS
AN 2001:115125 CAPLUS
DN 134:178566
TI Preparation of melanocortin-4 receptor binding compounds
IN Maguire, Martin P.; Dai, Mingshi; Vos, Tricia J.
PA Millennium Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 215 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001010842	A2	20010215	WO 2000-US21327	20000804
	WO 2001010842	A3	20010816		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1999-147288 P 19990804
US 2000-223277 P 20000803
OS MARPAT 134:178566
GI

CAS ONLINE PRINTOUT



I



II

AB The title compds. of formula B-Z-E [wherein B = an anchor moiety; Z = a central moiety; E = an MC4-R interacting moiety], e.g. I [wherein P2, P3, and P4 = independently CH, CF, CCl, CBr, C(alkyl), C(alkoxy), C(CN), C(OH), or CI; W1 = covalent bond or CH2; W2 = CH2, CHR3, or CR3R4; W3 = CH2, CHR5, or CR5R6; R = H or alkyl; Z1 = CH or covalently linked to Z2 to form a naphthyl ring; Z2 = CH, C(C.tplbond.CH), CCl, CBr, CI, CF, or covalently linked to Z1 to form a naphthyl ring; Z5 = CH or C(OMe); R3-R6 = independently Me or Et], were prepd. and tested as melanocortin-4 receptor (MC4-R) binding agonists and antagonists. For example, .alpha.-tolunitrile in THF was added to a soln. of diisopropylamine in THF, which had been cooled to -78.degree.C and treated with BuLi. HMPA and 1-chloromethylnaphthalene in THF were added, the reaction cooled and stirred for 1 h, and the reaction quenched with H2O to give 2-(2-naphthalen-1-ylethyl)benzonitrile. Treatment with H2S and 1,3-diaminopropane, followed by heating to 80.degree.C for 72 h and work up, gave II. In a scincillation proximity assay (SPA) using high-throughput receptor binding screening, II showed exemplary inhibition of MC4-R. The invention compds., primarily 2-(2-arylalkylsulfanylphenyl)-4,5-dihydro-1H-imidazole and 1,4,5,6-tetrahydropyrimidine derivs., are useful in the treatment of disorders assocd. with wt. loss and pigmentation (no data).

IT **326486-16-2P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(inactive as MC4-R binding compd.; prepn. and high throughput MC4-R receptor binding screening of arylalkylsulfanylphenyl-substituted imidazoles and pyrimidines and analogs)

RN 326486-16-2 CAPLUS

CN 1,2-Ethanediamine, N,N-dimethyl-N'-(2-phenylethyl)-N'-(phenylmethyl)-(9CI) (CA INDEX NAME)



L15 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2001 ACS

AN 1988:36842 CAPLUS

DN 108:36842

TI New synthetic "tricks". From aliphatic amines and amides to azides and/or how to convert RNHCOR' into RNHCOR" avoiding drastic hydrolyses

AU Garcia, Jordi; Vilarrasa, Jaume

CS Fac. Quim., Univ. Barcelona(III), Barcelona, 08028, Spain

SO Tetrahedron Lett. (1987), 28(3), 341-2
CODEN: TELEAY; ISSN: 0040-4039

CAS ONLINE PRINTOUT

DT Journal
LA English
OS CASREACT 108:36842
AB Controlled redn. of N-alkyl-N-nitrosoamides to hydrazides followed by nitrosation and fragmentation affords azides in 80% overall yields, under mild conditions. This simple idea is the basis of methods for the conversion of alkylamines and N-alkylamides to alkyl azides, of RNHCOR1 into RNHCOR2 or RN(COR3)2, and of lactams into .omega.-azido esters or .omega.-azido acids.
IT **112157-90-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 112157-90-1 CAPLUS
CN Benzeneacetic acid, 1-(phenylmethyl)hydrazide (9CI) (CA INDEX NAME)



L15 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2001 ACS
AN 1979:507817 CAPLUS
DN 91:107817
TI Phenylacetamide compounds
IN Ajisawa, Yukiyoshi; Kamijo, Tetsuhide; Saito, Takenao
PA Kissei Pharmaceutical Co., Ltd., Japan
SO Belg., 26 pp.
CODEN: BEXXAL
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	BE 870992	A1	19790201	BE 1978-190893	19781003
	JP 54055544	A2	19790502	JP 1977-119780	19771005
	JP 57005219	B4	19820129		
	GB 2006196	A	19790502	GB 1978-38905	19781002
	SE 7810421	A	19790406	SE 1978-10421	19781004
	DE 2843328	A1	19790419	DE 1978-2843328	19781004
	FR 2405240	A1	19790504	FR 1978-28383	19781004
	NL 7810053	A	19790409	NL 1978-10053	19781005
PRAI	JP 1977-119780		19771005		

GI



I

AB Phenylacetic acids and acid chlorides reacted with ethylenediamines to give title compds. I [R = C1-3 alkoxy; R1, R2 (same or different) = C1-3 alkyl, or NR1R2 = heterocyclyl; R3 = H, C1-3 alkyl; R4 = H, C1-3 alkoxy; n, m (same or different) = 0, 1, or 2), which exhibited analgesic activity. Thus, a mixt. of 4-MeOC6H4CH2CO2H and PhCH2CH2NHCH2CH2NEt2 was heated 6-8 h at 130-40.degree. and worked up to give I [R = 4-MeO (n = 1),

CAS ONLINE PRINTOUT

R1 = R2 = Et, R3 = R4 = H, m = 2].

IT **71108-98-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 71108-98-0 CAPLUS

CN Benzeneacetamide, N-[2-(diethylamino)ethyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L15 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2001 ACS

AN 1971:99273 CAPLUS

DN 74:99273

TI Sigmatropic rearrangements of diazenes

AU Baldwin, Jack E.; Brown, James Edward; Hoefle, Gerhard

CS Dep. Chem., Massachusetts Inst. Technol., Cambridge, Mass., USA

SO J. Amer. Chem. Soc. (1971), 93(3), 788-9
CODEN: JACSAT

DT Journal

LA English

AB Allylic hydrazines RN(NH2)CH2CH:CR1R2 are treated with HgO to give allylic azo compds. RN:NCR1R2CH:CH2 (I). I are obtained via diazenes RN+(:N-)CH2CH:CR1R2. Small amts. of hydrocarbons R2RCR1R2C:CH2, and CH2:CHCR1R2CR1R2CH:CH2 are also obtained but not from diazene intermediates.

IT **31908-23-3**
RL: RCT (Reactant)
(oxidn. of)

RN 31908-23-3 CAPLUS

CN Hydrazine, 1-benzyl-1-cinnamyl-, (E)- (8CI) (CA INDEX NAME)

Double bond geometry as shown.



=>